Posts

7 days in healthcare (February 12th-18th, 2024)

/in /by

Summary

From the point of view of Biomedicine, as is known, most rare diseases have no treatment, although this situation will surely be overcome in the not too distant future. A new drug (prozelimab) against the rare Chaple disease. A trial offers hope that a jab could prevent rheumatoid arthritis, the disease that affects 18 million people globally. Chances of a blood protein test warning about the onset of Alzheimer’s disease up to fifteen years in advance. A new powerful antibiotic (cresomycin), hope for antimicrobial resistance, which globally causes about five million deaths a year.

Regarding Global Health, despite the fact that 2021 marked the 100th anniversary of the appearance of insulin, many diabetes patients still do not have access to it. Important article in the New England Journal Medicine about e-cigarettes. There is sufficient evidence to show that switching from cigarettes to e-cigarettes reduces exposure to tobacco toxins, decreases respiratory symptoms, and reverses physiological changes related to cigarette smoking. There is not enough evidence that e-cigarettes are a good method to quit smoking.

In terms of International Health Policy, an unexpected consequence of the ruling of the United States Supreme Court, granting states the possibility of legislating on abortion, what was widely used to prohibit or restrict it: the taking of prescribed abortion pills by telemedicine and received by mail is a safe and effective method, according to a study. The European Commission approves the first gene editing treatment, in this case for beta thalassemia and sickle cell anemia. HERA (Health Emergency Preparedness and Response Authority) launches the Critical Medicines Alliance. It is said that this Alliance will contribute to changing the way medicines are produced and purchased in Europe.

If we talk about National Health Policy (Spain), there is great commotion in the sector as a result of the statements by Vice President Yolanda Díaz that she is negotiating to introduce in the budgets the modification of the health VAT from 0% to 21%. Regardless of the viability of this proposal, could it be considered whether this is the best way to make policy? Any study on the impact on the sector? Any previous negotiations with the health ecosystem? Although the Ministry of Health usually intervenes little in economic matters – remember that all the cuts during the financial crisis were not even discussed in the Interterritorial Council of the National Health System – this is a major issue that well deserves a position. and an analysis by the Ministry of Health. Asturias regulates financial compensation to professionals (442 euros for four hours of surgical activity and half for consultations for doctors) for extension of working hours to address the serious problem of waiting lists. Family doctors report a deficit of 2,600 professionals in the next year. As a consequence of the European Plan against Cancer, the launch of the first nine Comprehensive Cancer Centers in Spain is announced. The project is led in Spain by the Vall d’Hebron Hospital and the National Institute of Oncology.

As for Companies, on an international level, the British consulting firm Clarivate analyzes the 13 disruptive drugs for 2024. Oncology drugs predominate, although there is also the vaccine against respiratory syncytial virus and a new drug against COPD. At the national level, the growth of the egg freezing business in Spain is confirmed. It seems that the HIPRA vaccine is going to end up in the trash. There is nothing special, since failures are inherent to business, especially in an area as difficult as biotechnology. However, some excessively triumphalist government demonstrations could have been avoided.

Biomedicine

Global Health

International health policy

  • United Kingdom and the National Health Service

National health policy

Companies

7 days in healthcare (May 1st-7th, 2023)

/in /by

 

Summary

From the point of view of Biomedicine, to point out the interest in certain therapies using viruses that engulf bacteria to address infections caused by antibiotic-resistant bacteria. Progress continues to be made in breaking the blood-brain barrier, which will make it possible to better treat certain brain tumors, which until now have not been reached by medication.

As regards Global Health, the WHO declares the end of the emergency due to the covid pandemic, although not the covid, which is still with us. Since its inception this disease has caused more than 20 million deaths globally. Gavi reveals his plans for a malaria vaccine, another major global plague.

As for International Health Policy, he has highlighted the rise in the price of tobacco in France (a good measure against smoking), and Australia wants to limit the use of electronic cigarettes. The ECDC brings out an interesting report with the lessons of the pandemic: “More investment, improvement of surveillance systems, improvement of risk communication, community participation and greater participation between countries” could be the summary.

If we talk about National Health Policy (Spain), in the update of the Stability Program 2023-2026, the % of GDP dedicated to public healthcare spending does not change, remaining at 6.9%. It is evident that only increasing spending does not solve the problems of our health system, but it is difficult to see how they can be solved without increasing spending, as the government proposes. The Spanish Association against Cancer, through the mouth of its president, denounces that Spain has the cheapest tobacco in Europe: “the tobacconist of Europe” calls for this situation. Interesting article by Juan Abarca Cidón, who presents a decalogue to avoid the collapse of our health system. The measurements are very clear and direct. It will be possible to qualify or even disagree with some, but there is no doubt that the problems are addressed. Not like the framework programs of the majority parties for the 28-M elections, which seem to try not to raise any suspicion, by saying nothing.

At the Corporate level, at the international level, Lilly presents a new drug that slows down the progression of Alzheimer’s. The birth of a large market linked to Artificial Intelligence in health is in sight, according to the report by Siemens Financial Services. As far as our country is concerned, Cofares reaches a sales record in 2022. Grifols enters the field of leukemia.

Biomedicine

Global Health

International Health Policy

National health policy

  • Interesting article with a decalogue of reforms in our health system
    • Article by Juan Abarca Cidón, the proposals range from a political agreement; increase general spending on health; finalist financing with certain objectives; reduce costs, considering the co-payment; new governance model at all levels; new care organization model with a greater role for nursing; deal with patient problems, such as waiting lists; address the problems of professionals; normalize the activity of the private sector; and promote the Public Health Agency (https://www.elespanol.com/edicion/20230430/decalogo-reformas-evitar-colapso-sanidad/760293970_12.html)

Companies